London-listed SPAC targets merger with chronic disease drug developer Istesso

  • 📰 SkyNews
  • ⏱ Reading Time:
  • 29 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 67%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Hambro Perks Acquisition Company, the first SPAC to list in London in the wake of regulatory changes, is in advanced talks to merge with drug developer Istesso, Sky News learns.

The first ‘blank cheque’ company to list in London after an overhaul aimed at helping the City compete with rival financial centres is in talks to merge with a privately owned drugs group developing treatments for chronic diseases.

Founded in 2017, Istesso focuses on an area of medicine called immunometabolism, and is developing treatments for severe diseases such as arthritis and multiple sclerosis. Istesso is majority-owned by IP Group, the London-listed company which focuses on commercialising intellectual property across sectors such as energy and healthcare.

The SPAC, which raised nearly £150m from its initial public offering, had 15 months to secure a deal, meaning it faces a deadline next month to announce the merger or seek an extension from shareholders.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 35. in BR

Brasil Últimas Notícias, Brasil Manchetes